Gilead Sciences Inc. said Monday that its experimental anti-coronavirus drug remdesivir will be supplied to the governments of developed countries at what it sees as an affordable price of $2,340 per patient for a typical five-day treatment course.

The U.S. biopharmaceutical company has been donating worldwide, including to Japan, doses of the anti-viral drug that has demonstrated patient improvement in clinical trials for the disease triggered by the novel coronavirus. But it had not been clear what the price tag of the drug would be after the donations ended.

The U.S. Department of Health and Human Services said it has secured more than 500,000 treatment courses of the drug for the country's hospitals through September, which represents most of Gilead's projected production for the three months from July.

A treatment course of remdesivir is, on average, about six vials, according to the department.

Gilead said in a press release that it will charge governments $390 per vial.